

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-7 (Cancelled).

8. (Currently Amended) A composition for gene therapy ~~used for treating a disease susceptible to gene therapy,~~ transfecting a target cell at a site of vascularization in vivo, which contains as active ingredients:

(1) an effective amount for transfecting a target cell at a site of vascularization of a retrovirus that contains a gene ~~useful for gene therapy~~ to be transfected;

(2) an effective amount for transfecting a target cell at a site of vascularization of a functional substance having heparin-II-binding domain of fibronectin wherein said functional substance is CH-296; and

(3) an effective amount for transfecting a target cell at a site of vascularization of ~~vaseular~~ human umbilical vein endothelial cells.

Claims 9-41 (Cancelled).

42. (Currently Amended) The composition according to claim 8, wherein a protein encoded by the gene useful for

gene-therapy transfecting a target cell at a site of
vascularization is a therapeutic protein which is expressed
upon expression of the gene in the target cell in an amount
sufficient for the treatment.

43. (Previously Presented) The composition
according to claim 42, wherein the protein is an enzyme or a
cytokine.

Claims 44-50 (Cancelled).